ATE166867T1 - Azacyclische verbindungen, sie enthaltende zusammensetzungen und ihre verwendung als tachykinin antagoniste - Google Patents
Azacyclische verbindungen, sie enthaltende zusammensetzungen und ihre verwendung als tachykinin antagonisteInfo
- Publication number
- ATE166867T1 ATE166867T1 AT94907565T AT94907565T ATE166867T1 AT E166867 T1 ATE166867 T1 AT E166867T1 AT 94907565 T AT94907565 T AT 94907565T AT 94907565 T AT94907565 T AT 94907565T AT E166867 T1 ATE166867 T1 AT E166867T1
- Authority
- AT
- Austria
- Prior art keywords
- optionally substituted
- 6alkyl
- pct
- compounds
- tachykin
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 150000004030 azacyclic compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 2
- 241000689227 Cora <basidiomycete fungus> Species 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 102000003141 Tachykinin Human genes 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 108060008037 tachykinin Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939303243A GB9303243D0 (en) | 1993-02-18 | 1993-02-18 | Therapeutic agents |
| GB939322150A GB9322150D0 (en) | 1993-10-27 | 1993-10-27 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE166867T1 true ATE166867T1 (de) | 1998-06-15 |
Family
ID=26302480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94907565T ATE166867T1 (de) | 1993-02-18 | 1994-02-10 | Azacyclische verbindungen, sie enthaltende zusammensetzungen und ihre verwendung als tachykinin antagoniste |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5633266A (de) |
| EP (1) | EP0683767B1 (de) |
| JP (1) | JPH08506823A (de) |
| AT (1) | ATE166867T1 (de) |
| AU (1) | AU679207B2 (de) |
| CA (1) | CA2152925A1 (de) |
| DE (1) | DE69410784T2 (de) |
| ES (1) | ES2116583T3 (de) |
| WO (1) | WO1994019323A1 (de) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111960A (en) * | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| AU685212B2 (en) * | 1994-01-13 | 1998-01-15 | Merck Sharp & Dohme Limited | Gem-disubstituted azacyclic tachykinin antagonists |
| GB9402688D0 (en) * | 1994-02-11 | 1994-04-06 | Merck Sharp & Dohme | Therapeutic agents |
| EP0758329A1 (de) * | 1994-05-05 | 1997-02-19 | MERCK SHARP & DOHME LTD. | Morpholin-derivate und deren verwendung als antagonisten von tachykininen |
| DE19504627A1 (de) * | 1995-02-13 | 1996-08-14 | Bayer Ag | Verfahren und neue Zwischenprodukte zur Herstellung von Triazolinonen |
| GB9513117D0 (en) * | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
| GB9513121D0 (en) * | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
| US6013631A (en) | 1998-06-19 | 2000-01-11 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) deletion analogs |
| EP1299100B1 (de) * | 2000-06-12 | 2007-07-25 | The University Of Rochester | Methode zur behandlung von hitzewallungen, durch verwendung eines tachikinin-rezeptor antagonisten |
| US7407480B2 (en) * | 2001-07-27 | 2008-08-05 | Ams Research Corporation | Method and apparatus for correction of urinary and gynecological pathologies, including treatment of incontinence cystocele |
| US20060205724A1 (en) * | 2002-05-29 | 2006-09-14 | The Regents Of The University Of California | Antagonizing nk-1 receptors inhibits consumption of substances of abuse |
| CA2573271C (en) | 2004-07-15 | 2015-10-06 | Amr Technology, Inc. | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| JPWO2006030975A1 (ja) * | 2004-09-17 | 2008-05-15 | 武田薬品工業株式会社 | ピペリジン誘導体およびその用途 |
| WO2006115285A1 (ja) * | 2005-04-21 | 2006-11-02 | Takeda Pharmaceutical Company Limited | 医薬組成物 |
| EP1888050B1 (de) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs |
| JP5258561B2 (ja) | 2005-07-15 | 2013-08-07 | アルバニー モレキュラー リサーチ， インコーポレイテッド | アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用 |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| MX2009007200A (es) | 2007-01-10 | 2009-07-15 | Angeletti P Ist Richerche Bio | Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp). |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| AU2008269154B2 (en) | 2007-06-27 | 2014-06-12 | Merck Sharp & Dohme Llc | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| JP2011506441A (ja) * | 2007-12-12 | 2011-03-03 | アムジエン・インコーポレーテツド | グリシン輸送体−１阻害薬 |
| JP2011515343A (ja) | 2008-03-03 | 2011-05-19 | タイガー ファーマテック | チロシンキナーゼ阻害薬 |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| WO2010132437A1 (en) | 2009-05-12 | 2010-11-18 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| KR20120023072A (ko) | 2009-05-12 | 2012-03-12 | 브리스톨-마이어스 스큅 컴퍼니 | （Ｓ）-7-（〔1,2,4〕트리아졸〔1,5-ａ〕피리딘-6-일）-4-（3,4-디클로로페닐）-1,2,3,4-테트라하이드로이소퀴놀린의 결정형 및 이의 용도 |
| AU2010247763B2 (en) | 2009-05-12 | 2015-12-24 | Albany Molecular Research, Inc. | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
| EA023838B1 (ru) | 2009-10-14 | 2016-07-29 | Мерк Шарп Энд Домэ Корп. | ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ |
| EP2584903B1 (de) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Neue heterozyklische verbindungen als erk-hemmer |
| WO2012018754A2 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| CA2807307C (en) | 2010-08-17 | 2021-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
| EP2608669B1 (de) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer |
| US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| EP2615916B1 (de) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Kondensierte pyrazolderivate als neue erk-hemmer |
| US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
| EP2654748B1 (de) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
| AU2012245971A1 (en) | 2011-04-21 | 2013-10-17 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| EP3453762B1 (de) | 2012-05-02 | 2021-04-21 | Sirna Therapeutics, Inc. | Sina-zusammensetzungen |
| JP6280554B2 (ja) | 2012-09-28 | 2018-02-14 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｅｒｋ阻害剤である新規化合物 |
| ME02925B (de) | 2012-11-28 | 2018-04-20 | Merck Sharp & Dohme | Zusammensetzungen und verfahren zur behandlung von krebs |
| TW201429969A (zh) | 2012-12-20 | 2014-08-01 | Merck Sharp & Dohme | 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶 |
| EP2951180B1 (de) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8-substituierte purine als hdm2-inhibitoren |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US11993602B2 (en) | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| EP3833667B1 (de) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6033439B2 (ja) * | 1980-03-07 | 1985-08-02 | 財団法人相模中央化学研究所 | ジペプチドの製造方法 |
| WO1991009844A1 (en) * | 1990-01-04 | 1991-07-11 | Pfizer Inc. | Substance p antagonists |
| ATE154354T1 (de) * | 1991-02-11 | 1997-06-15 | Merck Sharp & Dohme | Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung |
| EP0600952B1 (de) * | 1991-08-20 | 1996-04-17 | MERCK SHARP & DOHME LTD. | Azacyclische verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen |
| US5444074A (en) * | 1992-04-15 | 1995-08-22 | Merck Sharp & Dohme Limited | Piperidine tachykinin receptor antagonists |
| AU675786B2 (en) * | 1992-04-15 | 1997-02-20 | Merck Sharp & Dohme Limited | Azacyclic compounds |
| US5496833A (en) * | 1993-04-13 | 1996-03-05 | Merck Sharp & Dohme Limited | Piperidine tachykinin receptor antagonists |
-
1994
- 1994-02-10 CA CA002152925A patent/CA2152925A1/en not_active Abandoned
- 1994-02-10 US US08/495,429 patent/US5633266A/en not_active Expired - Fee Related
- 1994-02-10 AU AU61093/94A patent/AU679207B2/en not_active Ceased
- 1994-02-10 JP JP6518622A patent/JPH08506823A/ja not_active Ceased
- 1994-02-10 DE DE69410784T patent/DE69410784T2/de not_active Expired - Fee Related
- 1994-02-10 EP EP94907565A patent/EP0683767B1/de not_active Expired - Lifetime
- 1994-02-10 WO PCT/EP1994/000412 patent/WO1994019323A1/en active IP Right Grant
- 1994-02-10 ES ES94907565T patent/ES2116583T3/es not_active Expired - Lifetime
- 1994-02-10 AT AT94907565T patent/ATE166867T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2116583T3 (es) | 1998-07-16 |
| AU6109394A (en) | 1994-09-14 |
| CA2152925A1 (en) | 1994-09-01 |
| US5633266A (en) | 1997-05-27 |
| EP0683767A1 (de) | 1995-11-29 |
| DE69410784T2 (de) | 1999-01-14 |
| JPH08506823A (ja) | 1996-07-23 |
| AU679207B2 (en) | 1997-06-26 |
| WO1994019323A1 (en) | 1994-09-01 |
| EP0683767B1 (de) | 1998-06-03 |
| DE69410784D1 (de) | 1998-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE166867T1 (de) | Azacyclische verbindungen, sie enthaltende zusammensetzungen und ihre verwendung als tachykinin antagoniste | |
| ATE192737T1 (de) | Aralkoxy und aralkylthio substituierte azacyclische verbindungen als tachykinin antagonisten | |
| ES2141174T3 (es) | 4-arilmetiloximetil piperidinas como antagonistas de taquiquinina. | |
| EP0611301A4 (de) | Chelat-zubereitungen, die oximverbindungen enthalten. | |
| BG105271A (en) | 1h-imidazopyridine derivatives | |
| DE69504300D1 (de) | Gem-bissubstituierte azazyclische tachykinin-antagonisten | |
| MXPA02011417A (es) | 1-aminoalquil-lactamas sustituidas y su uso como antagonistas de receptores muscarinicos. | |
| ATE127808T1 (de) | Atp-analogen. | |
| DK0502169T3 (da) | Piperazinderivater | |
| FR2673427B1 (fr) | Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant. | |
| MXPA02011418A (es) | 1-aminoalquil-lactamas sustituidas y su uso como antagonistas del receptor muscarinico. | |
| MY113945A (en) | Amino substituted pyrimidines and triazines | |
| ATE284692T1 (de) | Verwendung von nicht-peptidischen bradykinin- antagonisten zur herstellung von arzneimitteln zur behandlung und prävention der alzheimerischen krankheit | |
| ATE148741T1 (de) | Reinigendes desinfektionsmittel | |
| SE7710783L (sv) | Alfa-(4-bifenylyl)-bensyl-azolium-salter till anvendning for bekempning av mikroorganismer och sett att framstella foreningarna | |
| BR9508676A (pt) | Carbamolicarboxamida composição processos para preparar compostos e a composição e para controlar fungos nocivos e uso compost e das composições | |
| YU43902A (sh) | Novi razgranati supstituisani amino derivati od 3-amino-1- -fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže | |
| DE69029861D1 (de) | N-acyl-substituierte azazyklische verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
| PL316964A1 (en) | O-acyl 4-phenyl cyclohexanol, yheir salts, therapeutic agents containing such compound as well as their application and method of obtaining them | |
| DE59807744D1 (de) | Verwendung von sulfonyloxadiazolonen als mikrobizide | |
| TW372955B (en) | Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | |
| HUP0003548A2 (hu) | Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények | |
| DE50001988D1 (de) | DOLLAR g(a)- DOLLAR g(a)' -SUBSTITUIERTE N-ALKYL-3-ALKENYLBENZOYL-PYRAZOL-DERIVATE | |
| FI803996L (fi) | 1-(2-propynyloxy)-2-amino-3-propanoletrar | |
| SE8205587D0 (sv) | 1,2,3-tiadiazol-5-yl-karbamid-derivat och sett att framstella dessa foreningar samt medel, innehallande foreningarna, med tillvextreglerande och avlovande verkan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |